Intuitive, integrated and efficient – world premiere of Philips’ next-generation Azurion image-guided therapy platform
September 01 2020 - 4:00AM
Intuitive, integrated and efficient – world premiere of Philips’
next-generation Azurion image-guided therapy platform
September 1, 2020
- New level of integration across imaging, physiology,
hemodynamic and informatics applications
- SmartCT guides acquisition of 3D CT-like images and provides
visualization and measurement tools
- Increased efficiency and flexibility with tableside access to
more modalities and intuitive control of the gantry
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced its next-generation Philips Azurion image-guided therapy
platform, marking an important step forward in optimizing clinical
and operational lab performance and expanding the role of
image-guided interventions in the treatment of patients. Intuitive,
integrated and efficient, the next-generation Azurion advances the
capabilities of the platform to further improve the quality and
efficiency of interventional procedures. The Azurion platform has
already achieved rapid global adoption and has been used in well
over two million procedures [1] worldwide since its introduction
three years ago.
In the past few decades, clinical practices around the world
have evolved to successfully treat more patients and perform more
complex procedures in interventional labs. However, with more staff
and technologies involved during these procedures, interventional
lab environments can become crowded and cluttered. In order to
enhance clinician focus and control during procedures, Philips has
integrated all the essential lab systems and tools into this new
version of the Azurion platform, making it an important step
forward in lab integration.
An industry-first, the Philips Azurion image-guided therapy
platform now integrates control of imaging, physiology, hemodynamic
and informatics applications, as well as intuitive control of the
gantry, at the tableside, allowing clinicians to control all
compatible applications from a single touch screen while performing
procedures. This can eliminate the need for clinicians to leave the
sterile field and step into an adjacent control room, as well as
supporting faster and better informed decision making.
Simplifying 3D imaging during interventional
proceduresWith this next-generation Azurion platform,
Philips is also introducing a new 3D imaging solution called
SmartCT [2]. With SmartCT, users are guided through the image
acquisition and can review and interact with the acquired CT-like
3D images on the tableside touch screen module using 3D
visualization and measurement tools. These tools have been designed
to support procedures in a range of clinical domains, including
neurology, oncology, and cardiovascular procedures. The use of 3D
imaging such as 3D RA or Cone Beam CT during interventional
procedures has been shown to improve outcomes [3] and reduce
radiation dose for both staff and patients [4].
“Our aim as an innovation company and global market leader in
image-guided therapy is to push the boundaries and set new industry
standards for delivering an outstanding experience for clinicians,
helping them to deliver superior care to every patient,” said
Ronald Tabaksblat, General Manager Image Guided Therapy Systems at
Philips. “This next-generation Azurion makes routine cardiovascular
procedures more efficient and supports the development of new
minimally-invasive techniques to treat complex diseases such as
stroke, lung cancer and spine disorders.”
"The integrated platform enables us to efficiently carry out
complex interventions at any time using a wide range of functions
such as IVUS and iFR co-registration,” said Dr. med. Alexander
Becker, head of the cardiac catheter laboratory at the Robert Bosch
Hospital in Stuttgart, Germany, and one of the first hospitals to
experience the new platform. “The use of the control panel by the
examiner is intuitive, combining different sources of information
to make patient evaluation much easier and faster.”
Seamless control and workflow during
proceduresWith the new Azurion platform, clinicians can
easily switch between imaging, physiology, hemodynamic and
informatics applications, including SmartCT and IntraSight – a
comprehensive suite of clinically proven iFR, FFR, IVUS and
co-registration modalities. Fully automatic position control
enables clinicians to intuitively control the position of the
gantry and table, as well as choosing from a wide range of stored
parameters. The new Azurion also includes advanced cybersecurity
features, new high-definition image display capabilities, and
advanced remote and proactive services. The platform is available
in three versions: complementing the Azurion 3 and 7 variants,
Philips now also offers the Azurion 5 to facilitate even more
tailored solutions to address specific customer needs. For more
information visit www.philips.com/azurion.
[1] Based on Philips’ internal case and procedure data.[2]
SmartCT is 510(k) pending and not available for sale in the USA.[3]
Miyayama et al., ‘Comparison of local control in transcatheter
arterial chemoembolization of hepatocellular carcinoma ≤6 cm with
or without intraprocedural monitoring of the embolized area using
cone beam computed tomography’, CVIR 2014.[4] Schott et al.,
‘Radiation dose in prostatic artery embolization using Cone Beam CT
and 3D roadmap software, JVIR 2019.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email:
mark.groves@philips.comTwitter: mark_groves
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Azurion image-guided therapy
- Azurion IntraSight tableside monitor
- Azurion SmartCT tableside monitor
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Sep 2023 to Sep 2024